No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract ENESTnd: Frontline nilotinib therapy shows improvement in long-term efficacy outcomes for patients in the chronic phase of newly diagnosed chronic myeloid leukemia

byKathleen Lau

February 4, 2021

in StudyGraphics

Hypertension and obesity associated with changes in retinal microvasculature for children

RelatedReports

Thoracic radiotherapy improves survival in small-cell lung cancer patients

Chronic Disease

Simvastatin (Zocor) in combination with paclitaxel (Taxol) may provide treatment benefit compared to paclitaxel alone for small cell lung cancer

April 15, 2026

Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization

Cardiology

Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk

April 9, 2026

Radiation plus hormone therapy may improve prostate cancer survival

Oncology

Pfizer’s Talzenna combo significantly delays prostate cancer progression

April 9, 2026

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

Endocrinology

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

March 30, 2026

#VisualAbstract: Fixed-dose, subcutaneous injection of pertuzumab and trastuzumab is noninferior to intravenous administration in HER2⁺ breast cancer

#VisualAbstract: Incidence and prevalence of melanomas and keratinocyte carcinomas have increased from 1990 to 2017

Non-TNF-targeted therapies more effective than anti-TNF agents in uncontrolled rheumatoid arthritis

Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression

$Phase II O-12-M1: Melflufen plus dexamethasone showed benefits in long-term survival outcomes in relapsed/refractory multiple myeloma$

Phase II O-12-M1: Melflufen plus dexamethasone showed benefits in long-term survival outcomes in relapsed/refractory multiple myeloma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports